glp-1 for mash Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Novo Nordisk GLP-1 Drug Meets

boulardii is uniquely resistant to antibiotics and does not compete with bacterial probiotics for the same ecological niches

What I did find interesting is over time, when you first had these drugs approved in 2015 through the end of 2024, there was an increase in the use and by 2024, what we are seeing is people being prescribed these medications who don't have the indication for it

Finished skin stimulationtest, humanskin irritation test completednon-irritant, so it is perfectfor sensitive skin

Research on this compound is still developing, and its use is intended for general wellness support, not medical or therapeutic purposes

It is not intended to diagnose, treat, or cure any condition